MindWalk Holdings (HYFT) AI Stock Analysis

Compare

422 Followers

Top Page

MindWalk Holdings

(NASDAQ:HYFT)

Select Model

Neutral 48 (OpenAI - 5.2)

Rating:48Neutral

Price Target:

$1.00

▼(-13.79% Downside)

Action:ReiteratedDate:03/14/26

The score is held down primarily by weak financial performance (persistent losses and cash burn) and bearish technical trends (below key moving averages with negative MACD). These are partially offset by a more positive earnings-call outlook highlighting strong revenue growth and early traction toward recurring revenue via an enterprise Lens AI contract, while valuation remains constrained by ongoing unprofitability.

Positive Factors

Recurring revenue from LensAI

The one-year enterprise LensAI contract creates contracted monthly revenue, shifting mix from project work to a SaaS-like model. That improves revenue predictability, increases customer lifetime value, supports scalable sales motions, and provides a durable base for margin expansion.

Sustained revenue growth and U.S. expansion

Consecutive strong quarters and doubling of U.S. sales indicate commercial traction and product-market fit in a larger addressable market. Durable top-line growth supports fixed-cost leverage, funds incremental R&D/commercial investment, and strengthens bargaining power for partnerships and future financing.

Platform and IP differentiation

Patented HIFT methodology plus the B Cell Llama platform and peer-reviewed results create technical differentiation and IP protection. This builds a durable competitive moat, enables licensing or higher‑margin services, and supports long-term value capture across biologics, multispecifics, and cell therapy adjacencies.

Negative Factors

Negative cash flow and limited runway

Persistent operating and free cash flow deficits mean the business is not self-funding and has constrained runway. Continued cash burn forces reliance on external financing, asset monetization, or dilutive measures, increasing execution risk and potentially slowing commercial and R&D plans if funding gaps emerge.

Deep, persistent net losses

Very large negative margins and recurring net losses erode equity and depress ROE, limiting internal capacity to fund growth. Until structural profitability is achieved, the company will need recurring external capital, which raises long-term dilution risk and constrains strategic flexibility.

Preclinical pipeline and financing execution risk

Core discovery programs are still preclinical and depend on upcoming readouts to validate value. Advancement requires successful science plus timely asset-level financing; delays or negative results would materially affect future revenues and increase the chance of asset sales or dilutive financings, raising long-term binary risk.

MindWalk Holdings (HYFT) vs. SPDR S&P 500 ETF (SPY)

Market Cap

$56.05M

Dividend YieldN/A

Average Volume (3M)448.65K

Price to Earnings (P/E)―

Beta (1Y)1.83

Revenue Growth-17.94%

EPS Growth21.43%

CountryUS

Employees102

SectorHealthcare

Sector Strength45

IndustryBiotechnology

Share Statistics

EPS (TTM)-0.06

Shares Outstanding46,711,864

10 Day Avg. Volume437,845

30 Day Avg. Volume448,646

Financial Highlights & Ratios

PEG Ratio0.05

Price to Book (P/B)0.85

Price to Sales (P/S)0.83

P/FCF Ratio-2.80

Enterprise Value/Market Cap1.18

Enterprise Value/Revenue3.64

Enterprise Value/Gross Profit6.10

Enterprise Value/Ebitda-6.25

Forecast

1Y Price Target

$5.00

Price Target Upside331.03% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

EPS Forecast (FY)-0.27

Revenue Forecast (FY)$16.08M

MindWalk Holdings Business Overview & Revenue Model

Company DescriptionMindWalk Holdings Corp. operates as a bio-native AI company. It focuses on the integration of artificial intelligence, multi-omics data, and advanced laboratory research to accelerate the discovery and development of biologics. The company, through its LensAI platform and HYFT technology, it partners with pharmaceutical and biotechnology companies to drive de-risk drug development and unlock therapeutic possibilities. The company was formerly known as ImmunoPrecise Antibodies Ltd. and changed its name to MindWalk Holdings Corp. in September 2025. The company was incorporated in 1983 and is headquartered in Austin, Texas.

MindWalk Holdings Earnings Call Summary

Earnings Call Date:Mar 12, 2026

(Q3-2026)

% Change Since: |

Next Earnings Date:Jul 23, 2026

Earnings Call Sentiment Positive

The call presented multiple strong commercial and scientific positives: robust revenue growth (Q3 +52% YoY, nine-month +45%), U.S. revenue doubling, the signing of the first enterprise recurring Lens AI platform contract, important preclinical pipeline discoveries (conserved dengue epitope, influenza conserved feature, GLP-1 activity vs semaglutide), peer-reviewed validation, and a new nanobody platform launch. Offsetting these strengths are higher operating expenses (notably S&M and R&D), a Q3 gross margin dip, ongoing net losses and cash burn ($10.1M YTD), and dependency on pending preclinical readouts and successful asset-level financing. Overall, the highlights—revenue acceleration, platform monetization, and differentiated scientific milestones—materially outweigh the lowlights tied to investment-driven losses and program-stage risk.

Q3-2026 Updates

Positive Updates

Strong Revenue Growth and U.S. Expansion

Q3 revenue of $4.2M, up 52% year over year from $2.7M. Nine-month revenue of $11.4M, up 45% versus $7.9M prior year. U.S. revenue doubled year over year to $2.6M (from $1.3M), reflecting strategic investments in Boston/Cambridge and North American commercial focus.

First Enterprise Lens AI Platform Contract — Recurring Revenue

Signed first one-year enterprise Lens AI platform contract structured as monthly recurring revenue, marking a shift from primarily project-based revenue toward a contracted, scalable enterprise SaaS model. Lens AI is being rolled out across the broader client base (~750 active clients).

Pipeline Milestones — Dengue Discovery

HIFT identified a single conserved functional epitope across all four dengue serotypes (a discontinuous epitope invisible to sequence alignment). Rabbit immunizations completed; binding confirmation expected imminently, then multiserotype neutralization testing — dengue positioned as near-term proof of concept.

Pipeline Milestones — Influenza and GLP-1 Progress

Influenza: screened >2,000 diverse sequences and identified a single conserved functional feature across all sequences; moving toward manufacturing of in silico lead candidate. GLP-1: independent third-party in vitro assay confirmed receptor activation with activity relative to semaglutide; a dual regimen linking GLP-1 to a second longevity pathway was also identified.

Platform & IP Strength — HIFT and Functional Adjacency

HIFT (patented biological representation) highlighted as a unique, non-sequence-based approach operating on invariant functional architecture. Advanced functional adjacency capability (identifying molecules with same therapeutic effect despite low sequence similarity) and initiated IP protection on that capability.

Peer-Reviewed Validation and New Platform Launch

Published peer-reviewed work in Biomacromolecules demonstrating wet lab nanobody discovery capabilities. Launched B Cell LAMA single B cell nanobody discovery platform; company claims functional (not just affinity) selection yields superior multivalent potency. Company also notes 15 molecules advanced to clinic across portfolio.

Improved YTD Gross Margin and Cash Position

Nine-month gross margin improved to 58% from 53% a year ago (+5 percentage points). Company ended Q3 with $14.2M in cash and reports cash used in operations of $10.1M YTD, with divestiture proceeds from Netherlands redeployed into commercial growth and pipeline development.

Negative Updates

Quarterly Gross Margin Compression

Q3 gross margin declined to 59% from 65% in the prior-year quarter (a 6 percentage point drop), attributed to business mix variability despite YTD improvement.

Rising Operating Expenses

Q3 R&D rose to $1.2M from $0.9M (+33%), Q3 Sales & Marketing increased to $1.8M from $1.1M (+~64%), and Q3 G&A increased to $3.1M from $2.8M (+~11%), reflecting investment in commercial expansion and pipeline/platform development.

Ongoing Net Loss and Cash Burn

Net loss from continuing operations of $3.9M in Q3 and $11.2M for the nine months (although prior-year figures included a $21.2M impairment). Cash used in operations YTD of $10.1M and cash balance of $14.2M highlight limited near-term runway if higher burn continues or additional funding is delayed.

Pipeline Still Preclinical and Dependent on Near-Term Readouts

Key pipeline programs (dengue neutralization, influenza lead manufacturing, GLP-1 further development) remain preclinical or early-stage; pivotal validation (e.g., dengue neutralization assays) is pending and outcomes will materially affect program value.

Asset-Level Financing and Timing Uncertainty

Company is designing structured asset-level financing vehicles for proprietary programs but timelines and outcomes are uncertain; successful ring-fencing and external financing will be needed as programs advance and costs rise.

Concentration and Transition Risks

First enterprise platform contract is a meaningful commercial validation but introduces client concentration and execution risk as company transitions from project-based to recurring models and works to convert additional clients over an unspecified timeline.

Company Guidance

Management guided that recent momentum — Q3 revenue of C$4.2M (up 52% from C$2.7M a year ago), U.S. revenue doubling to C$2.6M from C$1.3M, and nine‑month revenue of C$11.4M (up 45% from C$7.9M) — plus the signing of a one‑year enterprise Lens AI platform contract will shift the mix toward contracted, recurring monthly revenue and, with broader Lens AI adoption, drive margin expansion (Q3 gross margin 59% vs. 65% prior year; nine‑month 58% vs. 53%, +5 ppt); management reaffirmed ongoing investment while noting Q3 R&D of C$1.2M (nine months C$3.5M), sales & marketing of C$1.8M (nine months C$4.3M), G&A of C$3.1M (nine months C$9.5M) with G&A expected to be flat to modestly up, that cash of C$14.2M and YTD operating cash use of C$10.1M provide runway, and that asset‑level financing structures are being developed to monetize pipeline while they expect these investments to yield returns.

MindWalk Holdings Financial Statement Overview

Summary

Fundamentals are weak overall: TTM revenue declined (-11.2%), losses remain large (TTM net margin about -149%), and both operating cash flow and free cash flow are negative (about -$11.1M and -$11.9M). Balance sheet leverage is moderate (TTM debt-to-equity ~0.20), but equity has fallen and ROE is sharply negative (TTM ROE ~-140%).

Income Statement

Very Negative

TTM (Trailing-Twelve-Months) revenue declined (-11.2%), and profitability remains deeply negative despite a solid gross margin (~54.7%). Net losses persist across the full history provided, with TTM net margin still highly negative (about -149%), indicating the cost structure remains far ahead of the current revenue base. A positive is improving gross margin versus prior annual periods, but the overall earnings profile is still weak and volatile.

Balance Sheet

Neutral

Leverage looks moderate in TTM with debt-to-equity around 0.20, down meaningfully from the 2025 annual level (~0.57), which reduces balance-sheet risk. However, shareholder equity has fallen materially versus prior years, and returns on equity remain sharply negative (TTM ROE about -140%), reflecting ongoing losses and erosion of capital. Overall, the balance sheet is not heavily levered, but profitability-related pressure on equity is a key weakness.

Cash Flow

Negative

Cash generation is weak: TTM operating cash flow and free cash flow are both negative (about -$11.1M and -$11.9M), signaling continued cash burn. The latest period shows improvement in free cash flow growth, but the business is still not self-funding. Free cash flow is roughly in line with (and slightly larger than) net loss in TTM, which suggests losses are translating into real cash outflows rather than being purely non-cash.

Breakdown	TTM	Apr 2025	Apr 2024	Apr 2023	Apr 2022	Apr 2021
Income Statement
Total Revenue	18.21M	24.31M	24.81M	21.17M	19.80M	17.91M
Gross Profit	10.88M	11.50M	9.19M	7.32M	9.17M	11.40M
EBITDA	-10.62M	-28.89M	-23.22M	-21.55M	-12.27M	-4.60M
Net Income	-9.19M	-29.97M	-26.43M	-27.21M	-17.09M	-7.34M
Balance Sheet
Total Assets	23.17M	44.44M	59.99M	77.81M	93.49M	66.96M
Cash, Cash Equivalents and Short-Term Investments	14.18M	10.66M	3.46M	8.28M	29.96M	41.76M
Total Debt	3.55M	13.40M	13.68M	7.27M	2.77M	3.46M
Total Liabilities	8.19M	20.82M	26.07M	20.01M	18.36M	10.04M
Stockholders Equity	14.98M	23.63M	33.92M	57.80M	75.28M	56.92M
Cash Flow
Free Cash Flow	-11.89M	-7.21M	-5.64M	-21.33M	-11.18M	-2.03M
Operating Cash Flow	-11.15M	-6.41M	-4.25M	-19.83M	-9.92M	-600.00K
Investing Cash Flow	12.97M	-799.00K	-1.56M	-1.97M	-5.21M	-2.46M
Financing Cash Flow	201.94K	14.89M	1.02M	-621.00K	2.88M	43.38M

MindWalk Holdings Technical Analysis

Technical Analysis Sentiment

Negative

Last Price1.16

Price Trends

50DMA

1.59

Negative

100DMA

1.71

Negative

200DMA

1.71

Negative

Market Momentum

MACD

-0.09

Negative

RSI

40.90

Neutral

STOCH

28.17

Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HYFT, the sentiment is Negative. The current price of 1.16 is below the 20-day moving average (MA) of 1.20, below the 50-day MA of 1.59, and below the 200-day MA of 1.71, indicating a bearish trend. The MACD of -0.09 indicates Negative momentum. The RSI at 40.90 is Neutral, neither overbought nor oversold. The STOCH value of 28.17 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HYFT.

MindWalk Holdings Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
RLMD	59 Neutral	$614.66M	-3.32	-170.83%	―	―	37.37%
PMVP	53 Neutral	$77.33M	-0.84	-59.07%	―	―	-58.47%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
HYFT	48 Neutral	$56.05M	-6.63	-63.13%	―	-17.94%	21.43%
HOWL	44 Neutral	$39.97M	-1.37	-122.43%	―	-100.00%	-8.30%

* Healthcare Sector Average

Performance Comparison

HYFT

MindWalk Holdings

1.20

0.77

182.35%

XBIT

XBiotech

2.39

-1.07

-30.92%

RLMD

Relmada Therapeutics

5.86

5.56

1853.33%

PMVP

PMV Pharmaceuticals

1.45

0.21

16.94%

HOWL

Werewolf Therapeutics

0.82

-0.30

-26.52%

ESLA

Estrella Immunopharma

1.02

0.03

3.03%

MindWalk Holdings Corporate Events

MindWalk Holdings Delivers Q3 Revenue Surge and Secures First LensAI Platform Contract

Mar 12, 2026

On March 12, 2026, MindWalk Holdings reported Q3 fiscal 2026 results for the period ended January 31, 2026, posting revenue of C$4.2 million, up 52% year over year and marking a third straight quarter of revenue growth, with U.S. sales doubling to C$2.6 million. The company also improved year-to-date gross margin to 58% and narrowed its quarterly net loss from continuing operations to C$3.9 million, while maintaining C$14.2 million in cash and equivalents.

MindWalk secured its first one-year enterprise LensAI platform contract with its largest AI client, shifting part of its business mix toward contracted recurring revenue and supporting its strategic push into North America, including new biologics services in Boston and Cambridge and the divestiture of European operations. Operationally it launched the B cell Llama nanobody discovery platform, advanced vaccine and therapeutic programs in dengue, GLP-1 and influenza based on LensAI-derived epitopes and pathways, and engaged advisors to structure asset-level financing around key pipeline assets, moves that collectively strengthen its AI-biologics positioning and create new funding and commercialization avenues for stakeholders.

The most recent analyst rating on (HYFT) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on MindWalk Holdings stock, see the HYFT Stock Forecast page.

MindWalk Holdings Files Q3 2026 MD&A and Interim Financials

Mar 12, 2026

MindWalk Holdings Corp. has filed a Form 6-K for March 2026, furnishing its management’s discussion and analysis and condensed interim consolidated financial statements for the three- and nine-month periods ended January 31, 2026 and 2025. The filing, approved by the board on March 11, 2026 and signed by CEO Jennifer Bath on March 12, 2026, also includes CEO and CFO certifications under Canadian regulations, reinforcing the company’s ongoing disclosure and compliance obligations to investors in Canada and the United States.

The most recent analyst rating on (HYFT) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on MindWalk Holdings stock, see the HYFT Stock Forecast page.

MindWalk Unveils B Cell Llama Nanobody Platform Backed by Peer-Reviewed Study

Mar 6, 2026

On March 6, 2026, MindWalk Holdings announced B Cell Llama, a new nanobody discovery platform built to generate llama-derived VHH single-domain antibodies for bispecifics, multispecific therapeutics and CAR-T cell therapies. The system extends its B Cell Select technology by directly harvesting VHH nanobodies from immunized llamas and layering LensAI across target selection, candidate triage and multispecific construct modeling.

The launch is backed by a peer‑reviewed Biomacromolecules study showing that modular VHH formats can boost potency 10–25 times, overcome variant resistance where approved antibodies fail and potentially prime long‑term immune memory. MindWalk, which holds first rights to commercialize joint IP from the work, positions B Cell Llama as a key pillar of its bio-native AI strategy and pipeline in areas such as dengue, universal influenza, GLP‑1 and longevity therapeutics, and ALK‑1 oncology, aiming to capture a share of the fast‑growing bispecific and cell therapy markets.

The most recent analyst rating on (HYFT) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on MindWalk Holdings stock, see the HYFT Stock Forecast page.

MindWalk Holdings Reports Record Growth and Strategic Advances

Dec 15, 2025

On December 15, 2025, MindWalk Holdings reported record financial growth for the second quarter of fiscal 2026, with a 54% increase in revenue and a 94% rise in gross profit year-over-year. The company also announced strategic advancements in its AI asset pipeline, including progress in its GLP1 receptor agonist program and a universal dengue vaccine initiative. MindWalk completed a corporate rebranding, expanded its leadership team, and divested its Netherlands operations to focus on its core BioNative AI initiatives. Additionally, the company is forming a Cayman Islands corporation to house segregated portfolios for its AI-driven programs, allowing direct investor participation. These developments are expected to enhance MindWalk’s industry positioning and operational capabilities.

The most recent analyst rating on (HYFT) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on MindWalk Holdings stock, see the HYFT Stock Forecast page.

MindWalk Holdings Emphasizes AI-Driven Strategy in Latest Financial Release

Dec 15, 2025

On December 15, 2025, MindWalk Holdings released its Management Discussion and Analysis for the three and six months ending October 31, 2025. The company is focusing on a software-led model centered on its LensAI platform, which integrates AI and data services for biologics discovery. This strategic shift aims to enhance revenue growth and operational efficiency. The release highlights the company’s efforts in research and development, particularly in dengue and GLP-1 programs, and emphasizes the importance of intellectual property protection. The announcement underscores MindWalk’s commitment to advancing its AI-driven solutions in the drug discovery industry, which may impact its market positioning and stakeholder interests.

The most recent analyst rating on (HYFT) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on MindWalk Holdings stock, see the HYFT Stock Forecast page.

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Mar 14, 2026